Successful treatment of chronic myeloid leukemia with tyrosine kinase inhibitors goes beyond access to drugs
AUTOR(ES)
Conchon, Monika
FONTE
Rev. Bras. Hematol. Hemoter.
DATA DE PUBLICAÇÃO
2013
RESUMO
Documentos Relacionados
- Importance of adherence to BCR-ABL tyrosine-kinase inhibitors in the treatment of chronic myeloid leukemia
- Brazilian chronic myeloid leukemia working group recommendations for discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia in clinical practice
- Treatment with dasatinib or nilotinib in chronic myeloid leukemia patients who failed to respond to two previously administered tyrosine kinase inhibitors - a single center experience
- Recommendations for the management of cardiovascular risk in patients with chronic myeloid leukemia on tyrosine kinase inhibitors: risk assessment, stratification, treatment and monitoring
- Serum concentrations of nitrite and malondialdehyde as markers of oxidative stress in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors